{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:20:06Z","timestamp":1791908406161,"version":"4.3.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jilin Provincial Department of Education Science and Technology Research Project","award":["JJKH20241078KJ"],"award-info":[{"award-number":["JJKH20241078KJ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03493-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:25:37Z","timestamp":1760444737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in immunotherapy for breast cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Yi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"3493_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3493_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/1055-9965","volume":"27","author":"RM Pfeiffer","year":"2018","unstructured":"Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1214\u201322. https:\/\/doi.org\/10.1158\/1055-9965.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"3493_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7326\/M16-2586","volume":"167","author":"A Tsodikov","year":"2017","unstructured":"Tsodikov A, Gulati R, Heijnsdijk EA, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449\u201355. https:\/\/doi.org\/10.7326\/M16-2586.","journal-title":"Ann Intern Med"},{"key":"3493_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10552-007-9083-8","volume":"19","author":"R Etzioni","year":"2008","unstructured":"Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175\u201381. https:\/\/doi.org\/10.1007\/s10552-007-9083-8.","journal-title":"Cancer Causes Control"},{"issue":"8","key":"3493_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.7150\/ijbs.60631","volume":"17","author":"X Wang","year":"2021","unstructured":"Wang X, Wang C, Guan J, Chen B, Xu L, Chen C. Progress of breast cancer basic research in China. Int J Biol Sci. 2021;17(8):2069. https:\/\/doi.org\/10.7150\/ijbs.60631.","journal-title":"Int J Biol Sci"},{"key":"3493_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1264090","volume":"13","author":"J Xie","year":"2023","unstructured":"Xie J, Gan L, Xue B, Wang X, Pei X. Emerging roles of interactions between NcRNAs and other epigenetic modifications in breast cancer. Front Oncol. 2023;13:1264090. https:\/\/doi.org\/10.3389\/fonc.2023.1264090.","journal-title":"Front Oncol"},{"key":"3493_CR7","doi-asserted-by":"publisher","first-page":"1170464","DOI":"10.3389\/fonc.2023.1332676","volume":"13","author":"X Liang","year":"2023","unstructured":"Liang X, Wang Y, Fu G, Fan P, Ma K, Cao X-C, et al. Top 100 cited classical articles in Sentinel lymph nodes biopsy for breast cancer. Front Oncol. 2023;13:1170464. https:\/\/doi.org\/10.3389\/fonc.2023.1332676.","journal-title":"Front Oncol"},{"issue":"5","key":"3493_CR8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000531943","volume":"18","author":"N AiErken","year":"2023","unstructured":"AiErken N, Shao N, Liu Y, Shi H, Shi Y, Yuan Z, et al. Effect of lipid levels on tumor-infiltrating lymphocytes and prognosis in patients with triple-negative breast cancer. Breast Care. 2023;18(5):390\u20138. https:\/\/doi.org\/10.1159\/000531943.","journal-title":"Breast Care"},{"key":"3493_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1247632","volume":"11","author":"S Swami","year":"2023","unstructured":"Swami S, Mughees M, Mangangcha IR, Kauser S, Wajid S. Secretome analysis of breast cancer cells to identify potential target proteins of Ipomoea turpethum extract-loaded nanoparticles in the tumor microenvironment. Front Cell Dev Biol. 2023;11:1247632. https:\/\/doi.org\/10.3389\/fcell.2023.1247632.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"3493_CR10","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18502\/ijph.v52i10.13857","volume":"52","author":"M Mousavi","year":"2023","unstructured":"Mousavi M, Hajizadeh E, Rasekhi A, Haghighat S. Evaluation factors affecting on recurrence, metastasis, and survival of breast cancer in Iranian women by Multi-State model approach. Iran J Public Health. 2023;52(10):2186. https:\/\/doi.org\/10.18502\/ijph.v52i10.13857.","journal-title":"Iran J Public Health"},{"issue":"1","key":"3493_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/imr.13283","volume":"320","author":"WW Wong","year":"2023","unstructured":"Wong WW, Lim WA. Golden age of immunoengineering. Immunol Rev. 2023;320(1):4\u20139. https:\/\/doi.org\/10.1111\/imr.13283.","journal-title":"Immunol Rev"},{"key":"3493_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105048","volume":"89","author":"D Chen","year":"2023","unstructured":"Chen D, Hu Y. Approaches for boosting antitumor immunity in prostate cancer therapy: a comprehensive review on drugs, products, and nanoparticles. J Drug Deliv Sci Technol. 2023;105048. https:\/\/doi.org\/10.1016\/j.jddst.2023.105048.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"3493_CR13","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/cancers15102721","volume":"15","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Yahya EB, Mohamed Ibrahim Mohamed M, Rashid S, Iqbal MO, Kontek R, et al. Recent advances in molecular mechanisms of cancer immunotherapy. Cancers. 2023;15(10):2721. https:\/\/doi.org\/10.3390\/cancers15102721.","journal-title":"Cancers"},{"issue":"11","key":"3493_CR14","doi-asserted-by":"publisher","first-page":"e2342107","DOI":"10.1001\/jamanetworkopen.2023.42107","volume":"6","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6(11):e2342107\u2013e. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.42107.","journal-title":"JAMA Netw Open"},{"key":"3493_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00262-010-0869-2","volume":"59","author":"MZ Ladjemi","year":"2010","unstructured":"Ladjemi MZ, Jacot W, Chard\u00e8s T, P\u00e8legrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 2010;59:1295\u2013312. https:\/\/doi.org\/10.1007\/s00262-010-0869-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"3493_CR16","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cells12172159","volume":"12","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, et al. Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells. 2023;12(17):2159. https:\/\/doi.org\/10.3390\/cells12172159.","journal-title":"Cells"},{"issue":"4","key":"3493_CR17","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/cam4.2763","volume":"9","author":"M Yarchoan","year":"2020","unstructured":"Yarchoan M, Huang CY, Zhu Q, Ferguson AK, Durham JN, Anders RA, et al. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med. 2020;9(4):1485\u201394. https:\/\/doi.org\/10.1002\/cam4.2763.","journal-title":"Cancer Med"},{"issue":"8","key":"3493_CR18","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90(8):3539\u201343. https:\/\/doi.org\/10.1073\/pnas.90.8.3539.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3493_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110696","volume":"123","author":"MK Vajari","year":"2023","unstructured":"Vajari MK, Sanaei M-J, Salari S, Rezvani A, Ravari MS, Bashash D. Breast cancer vaccination: latest advances with an analytical focus on clinical trials. Int Immunopharmacol. 2023;123:110696. https:\/\/doi.org\/10.1016\/j.intimp.2023.110696.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"3493_CR20","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen H, Mo H, Hu X, Gao R, Zhao Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 Blockade in triple-negative breast cancer. Cancer Cell. 2021;39(12):1578\u2013e938. https:\/\/doi.org\/10.1016\/j.ccell.2021.09. Epub 20211014.","journal-title":"Cancer Cell"},{"issue":"35","key":"3493_CR21","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1200\/JCO.2009.23.3494","volume":"27","author":"LA Emens","year":"2009","unstructured":"Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor\u2013secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27(35):5911\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.3494.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3493_CR22","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-08-3282","volume":"15","author":"PP Peethambaram","year":"2009","unstructured":"Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2\/neu. Clin Cancer Res. 2009;15(18):5937\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-3282.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3493_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/cas.13618","volume":"109","author":"Z Chen","year":"2018","unstructured":"Chen Z, Hu K, Feng L, Su R, Lai N, Yang Z, et al. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1\/programmed death ligand-1 as a vaccination approach against breast cancer. Cancer Sci. 2018;109(6):1753\u201363. https:\/\/doi.org\/10.1111\/cas.13618.","journal-title":"Cancer Sci"},{"issue":"33","key":"3493_CR24","doi-asserted-by":"publisher","first-page":"e2205462","DOI":"10.1002\/adma.202205462","volume":"34","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Fang L, Xiao P, Sun X, Zhou L, Liu X, et al. Walking dead tumor cells for targeted drug delivery against lung metastasis of Triple-Negative breast cancer. Adv Mater. 2022;34(33):e2205462. https:\/\/doi.org\/10.1002\/adma.202205462. Epub 20220715.","journal-title":"Adv Mater"},{"issue":"9","key":"3493_CR25","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.4049\/jimmunol.174.9.5481","volume":"174","author":"F Rohrbach","year":"2005","unstructured":"Rohrbach F, Weth R, Kursar M, Sloots A, Mittrucker H-W, Wels WS. Targeted delivery of the ErbB2\/HER2 tumor antigen to professional apcs results in effective antitumor immunity. J Immunol. 2005;174(9):5481\u20139. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5481.","journal-title":"J Immunol"},{"key":"3493_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007661","author":"Y Luo","year":"2023","unstructured":"Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, et al. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-007661.","journal-title":"J Immunother Cancer"},{"key":"3493_CR27","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105239","author":"PV Pham","year":"2016","unstructured":"Pham PV, Le HT, Vu BT, Pham VQ, Le PM, Phan NL-C, et al. Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. OncoTargets therapy. 2016. https:\/\/doi.org\/10.2147\/OTT.S105239.","journal-title":"OncoTargets therapy"},{"issue":"2","key":"3493_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/0008-5472.CAN-17-1980","volume":"78","author":"A Cauwels","year":"2018","unstructured":"Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 2018;78(2):463\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1980.","journal-title":"Cancer Res"},{"issue":"1","key":"3493_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","volume":"21","author":"L Huang","year":"2022","unstructured":"Huang L, Rong Y, Tang X, Yi K, Qi P, Hou J, et al. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022;21(1):45. https:\/\/doi.org\/10.1186\/s12943-022-01515-x. Epub 20220211.","journal-title":"Mol Cancer"},{"issue":"2","key":"3493_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JCO.21.02937","volume":"41","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Im S-A, Cardoso F, Cortes J, Curigliano G, Musolino A, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2023;41(2):198\u2013205. https:\/\/doi.org\/10.1200\/JCO.21.02937.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3493_CR31","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cancers14092136","volume":"14","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel). 2022;14(9):2136. https:\/\/doi.org\/10.3390\/cancers14092136.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"3493_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/imt.14.22","volume":"6","author":"EJ Schneble","year":"2014","unstructured":"Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax\u2122) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519\u201331. https:\/\/doi.org\/10.2217\/imt.14.22.","journal-title":"Immunotherapy"},{"key":"3493_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108679","volume":"225","author":"RC Chick","year":"2021","unstructured":"Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Bohan PMK, et al. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021;225:108679. https:\/\/doi.org\/10.1016\/j.clim.2021.108679.","journal-title":"Clin Immunol"},{"key":"3493_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101947","volume":"84","author":"C Solinas","year":"2020","unstructured":"Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020;84:101947. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101947.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"3493_CR35","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","volume":"25","author":"E Mittendorf","year":"2014","unstructured":"Mittendorf E, Clifton G, Holmes J, Schneble E, Van Echo D, Ponniah S, et al. Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25(9):1735\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdu211.","journal-title":"Ann Oncol"},{"issue":"3","key":"3493_CR36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1158\/1078-0432.CCR-07-1448","volume":"14","author":"GE Peoples","year":"2008","unstructured":"Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al. Combined clinical trial results of a HER2\/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res. 2008;14(3):797\u2013803. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1448.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"3493_CR37","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2005.03.047","volume":"23","author":"GE Peoples","year":"2005","unstructured":"Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, et al. Clinical trial results of a HER2\/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23(30):7536\u201345. https:\/\/doi.org\/10.1200\/JCO.2005.03.047.","journal-title":"J Clin Oncol"},{"key":"3493_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-021-02187-1","volume":"21","author":"Z You","year":"2021","unstructured":"You Z, Zhou W, Weng J, Feng H, Liang P, Li Y, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021;21:1\u201312. https:\/\/doi.org\/10.1186\/s12935-021-02187-1.","journal-title":"Cancer Cell Int"},{"issue":"40","key":"3493_CR39","doi-asserted-by":"publisher","first-page":"66192","DOI":"10.18632\/oncotarget.11751","volume":"7","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7(40):66192. https:\/\/doi.org\/10.18632\/oncotarget.11751.","journal-title":"Oncotarget"},{"issue":"2","key":"3493_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","volume":"181","author":"TA Brown","year":"2020","unstructured":"Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181(2):391\u2013401. https:\/\/doi.org\/10.1007\/s10549-020-05638-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"3493_CR41","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/cncr.21849","volume":"106","author":"EA Mittendorf","year":"2006","unstructured":"Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, et al. Evaluation of the HER2\/neu-derived peptide GP2 for use in a peptide\u2010based breast cancer vaccine trial. Cancer. 2006;106(11):2309\u201317. https:\/\/doi.org\/10.1002\/cncr.21849.","journal-title":"Cancer"},{"key":"3493_CR42","doi-asserted-by":"publisher","first-page":"828386","DOI":"10.3389\/fimmu.2022.828386","volume":"13","author":"S-Y Zhu","year":"2022","unstructured":"Zhu S-Y, Yu K-D. Breast cancer vaccines: disappointing or promising? Front Immunol. 2022;13:828386. https:\/\/doi.org\/10.3389\/fimmu.2022.828386.","journal-title":"Front Immunol"},{"issue":"1","key":"3493_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25(1):102\u201316. https:\/\/doi.org\/10.1038\/s41590-023-01687-8.","journal-title":"Nat Immunol"},{"issue":"1","key":"3493_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/13543784.2021.1849140","volume":"30","author":"PM McCarthy","year":"2021","unstructured":"McCarthy PM, Clifton GT, Vreeland TJ, Adams AM, O\u2019Shea AE, Peoples GE. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opin Investig Drugs. 2021;30(1):5\u201311. https:\/\/doi.org\/10.1080\/13543784.2021.1849140.","journal-title":"Expert Opin Investig Drugs"},{"issue":"24","key":"3493_CR45","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/s0264-410x(00)00067-0","volume":"18","author":"R Humphreys","year":"2000","unstructured":"Humphreys R, Adams S, Koldzic G, Nedelescu B, Von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine. 2000;18(24):2693\u20137. https:\/\/doi.org\/10.1016\/s0264-410x(00)00067-0.","journal-title":"Vaccine"},{"issue":"14","key":"3493_CR46","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.Ccr-18-2867","volume":"25","author":"EA Mittendorf","year":"2019","unstructured":"Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, et al. Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248\u201354. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2867.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3493_CR47","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.biotechadv.2015.10.013","volume":"33","author":"P Peres Lde","year":"2015","unstructured":"Peres Lde P, da Luz FA, Pultz Bdos A, Br\u00edgido PC, de Ara\u00fajo RA, Goulart LR, et al. Peptide vaccines in breast cancer: the immunological basis for clinical response. Biotechnol Adv. 2015;33(8):1868\u201377. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.10.013. Epub 20151030.","journal-title":"Biotechnol Adv"},{"key":"3493_CR48","first-page":"784","volume":"29","author":"SS Patel","year":"2021","unstructured":"Patel SS, McWilliams DB, Patel MS, Fischette CT, Thompson J, Daugherty FJ, et al. Five year median follow-up data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the reduction of recurrences using HER2\/neu peptide GP2\u2009+\u2009GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. Surgery. 2021;29:784.","journal-title":"Surgery"},{"issue":"7","key":"3493_CR49","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","volume":"27","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016;27(7):1241\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw150.","journal-title":"Ann Oncol"},{"issue":"20","key":"3493_CR50","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/jco.2007.15","volume":"26","author":"JP Holmes","year":"2008","unstructured":"Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2\/neu peptide (AE37) vaccine. J Clin Oncol. 2008;26(20):3426\u201333. https:\/\/doi.org\/10.1200\/jco.2007.15. .7842. PubMed PMID: 18612158.","journal-title":"J Clin Oncol"},{"key":"3493_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1097983","volume":"13","author":"T Yang","year":"2023","unstructured":"Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol. 2023;13:1097983. https:\/\/doi.org\/10.3389\/fonc.2023.1097983.","journal-title":"Front Oncol"},{"issue":"17","key":"3493_CR52","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1158\/1078-0432.CCR-20-0389","volume":"26","author":"EJ Crosby","year":"2020","unstructured":"Crosby EJ, Acharya CR, Haddad A-F, Rabiola CA, Lei G, Wei J-P, et al. Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and \u03b1PD-1 enable sustained antitumor responses against established HER2 breast cancer. Clin Cancer Res. 2020;26(17):4670\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0389.","journal-title":"Clin Cancer Res"},{"key":"3493_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biomaterials.2016.12.030","volume":"121","author":"S Shukla","year":"2017","unstructured":"Shukla S, Myers JT, Woods SE, Gong X, Czapar AE, Commandeur U, et al. Plant viral nanoparticles-based HER2 vaccine: immune response influenced by differential transport, localization and cellular interactions of particulate carriers. Biomaterials. 2017;121:15\u201327. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.12.030.","journal-title":"Biomaterials"},{"issue":"9","key":"3493_CR54","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","volume":"25","author":"EJ Crosby","year":"2019","unstructured":"Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, et al. Vaccine-induced memory CD8\u2009+\u2009T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study. Clin Cancer Res. 2019;25(9):2725\u201336.","journal-title":"Clin Cancer Res"},{"key":"3493_CR55","first-page":"1213386","volume-title":"Nanobody-based cancer immunotherapy and immunoimaging","author":"M Jafari","year":"2023","unstructured":"Jafari M, Maali A, Shokrgozar MA, Sharifzadeh Z. Nanobody-based cancer immunotherapy and immunoimaging. Frontiers Media SA; 2023. p. 1213386."},{"key":"3493_CR56","doi-asserted-by":"publisher","first-page":"1292839","DOI":"10.3389\/fimmu.2023.1292839","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Luan L, Liu X, Jiang D, Deng J, Xu J, et al. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Front Immunol. 2023;14:1292839. https:\/\/doi.org\/10.3389\/fimmu.2023.1292839.","journal-title":"Front Immunol"},{"key":"3493_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119110","volume":"271","author":"N Hashemzadeh","year":"2021","unstructured":"Hashemzadeh N, Dolatkhah M, Adibkia K, Aghanejad A, Barzegar-Jalali M, Omidi Y, et al. Recent advances in breast cancer immunotherapy: the promising impact of nanomedicines. Life Sci. 2021;271:119110. https:\/\/doi.org\/10.1016\/j.lfs.2021.119110.","journal-title":"Life Sci"},{"key":"3493_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2018.06.035","volume":"285","author":"CYX Chua","year":"2018","unstructured":"Chua CYX, Jain P, Susnjar A, Rhudy J, Folci M, Ballerini A, et al. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. J Controlled Release. 2018;285:23\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2018.06.035.","journal-title":"J Controlled Release"},{"issue":"1","key":"3493_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/cas.16008","volume":"115","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab\u201077\u2010mG2a\u2010f. Cancer Sci. 2024;115(1):298\u2013309. https:\/\/doi.org\/10.1111\/cas.16008.","journal-title":"Cancer Sci"},{"issue":"1","key":"3493_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000528756","volume":"18","author":"C Suppan","year":"2023","unstructured":"Suppan C, Balic M. Current standards and future outlooks in metastatic Her2-positive breast cancer. Breast Care. 2023;18(1):69\u201375. https:\/\/doi.org\/10.1159\/000528756.","journal-title":"Breast Care"},{"key":"3493_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.breast.2023.06.007","volume":"70","author":"V Geurts","year":"2023","unstructured":"Geurts V, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen M, et al. Unleashing NK-and CD8 T cells by combining Monalizumab and trastuzumab for metastatic HER2-positive breast cancer: results of the MIMOSA trial. Breast. 2023;70:76\u201381. https:\/\/doi.org\/10.1016\/j.breast.2023.06.007.","journal-title":"Breast"},{"issue":"25","key":"3493_CR62","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.21.02772","volume":"40","author":"J Huober","year":"2022","unstructured":"Huober J, Barrios CH, Niikura N, Jarz\u0105b M, Chang Y-C, Huggins-Puhalla SL, et al. Atezolizumab with neoadjuvant anti\u2013human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2\u2013positive early breast cancer: primary results of the randomized phase III IMpassion050 trial. J Clin Oncol. 2022;40(25):2946\u201356. https:\/\/doi.org\/10.1200\/JCO.21.02772.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3493_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early Triple-Negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. doi: 10.1056\/NEJMoa1910549. PubMed PMID: 32101663.","journal-title":"N Engl J Med"},{"issue":"1","key":"3493_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3493_CR65","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim S-B, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283\u201395.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3493_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","volume":"20","author":"S Loi","year":"2019","unstructured":"Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20(3):371\u201382.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3493_CR67","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.4143\/crt.2021.1103","volume":"54","author":"Y-P Lee","year":"2022","unstructured":"Lee Y-P, Lee M-S, Kim H, Kim J-Y, Ahn JS, Im Y-H, et al. Real-world evidence of trastuzumab, pertuzumab, and docetaxel combination as a first-line treatment for Korean patients with HER2-positive metastatic breast cancer. Cancer Res Treat. 2022;54(4):1130. https:\/\/doi.org\/10.4143\/crt.2021.1103.","journal-title":"Cancer Res Treat"},{"key":"3493_CR68","doi-asserted-by":"publisher","first-page":"1194020","DOI":"10.3389\/fimmu.2023.1194020","volume":"14","author":"R Li","year":"2023","unstructured":"Li R, Cao L. The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy. Front Immunol. 2023;14:1194020. https:\/\/doi.org\/10.3389\/fimmu.2023.1194020.","journal-title":"Front Immunol"},{"issue":"1","key":"3493_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41590-023-01685-w","volume":"25","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Lou G, Teng X-L, Wang H, Luo Y, Shi W, et al. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells. Nat Immunol. 2024;25(1):117\u201328. https:\/\/doi.org\/10.1038\/s41590-023-01685-w.","journal-title":"Nat Immunol"},{"issue":"6","key":"3493_CR70","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, Tiruneh G, Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, et al. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccines Immunother. 2022;18(6):2114254. https:\/\/doi.org\/10.1080\/21645515.2022.2114254.","journal-title":"Hum Vaccines Immunother"},{"issue":"5","key":"3493_CR71","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1002\/cti2.1135","volume":"9","author":"L Xia","year":"2020","unstructured":"Xia L, Zheng Z, Jy L, Yj C, Jc D, Ns X, et al. EGFR-targeted CAR\u2010T cells are potent and specific in suppressing triple\u2010negative breast cancer both in vitro and in vivo. Clin Translational Immunol. 2020;9(5):e1135. https:\/\/doi.org\/10.1002\/cti2.1135.","journal-title":"Clin Translational Immunol"},{"key":"3493_CR72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200844","author":"N Xu","year":"2021","unstructured":"Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20200844.","journal-title":"J Exp Med"},{"key":"3493_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01168-1","volume":"14","author":"F Ji","year":"2021","unstructured":"Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021;14:1\u20135. https:\/\/doi.org\/10.1186\/s13045-021-01168-1.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"3493_CR74","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI87624","volume":"127","author":"TT Smith","year":"2017","unstructured":"Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127(6):2176\u201391. https:\/\/doi.org\/10.1172\/JCI87624.","journal-title":"J Clin Invest"},{"issue":"1","key":"3493_CR75","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/cancers16010168","volume":"16","author":"CE \u00d6nder","year":"2023","unstructured":"\u00d6nder CE, Moustafa-Oglou M, Schr\u00f6der SM, Hartkopf AD, Koch A, Seitz CM. Precision immunotherapy utilizing adapter CAR-T cells (AdCAR-T) in metastatic breast cancer leads to target specific lysis. Cancers. 2023;16(1):168. https:\/\/doi.org\/10.3390\/cancers16010168.","journal-title":"Cancers"},{"key":"3493_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. Front Immunol. 2023;14:1121030.","journal-title":"Front Immunol"},{"key":"3493_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005189","author":"D Lock","year":"2022","unstructured":"Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, et al. Automated, scaled, transposon-based production of CAR T cells. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005189.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3493_CR78","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1186\/s12885-022-10320-0","volume":"22","author":"M Bahmanyar","year":"2022","unstructured":"Bahmanyar M, Vakil MK, Al-Awsi GRL, Kouhpayeh SA, Mansoori Y, Mansoori B, et al. Anticancer traits of chimeric antigen receptors (CARs)-natural killer (NK) cells as novel approaches for melanoma treatment. BMC Cancer. 2022;22(1):1220. https:\/\/doi.org\/10.1186\/s12885-022-10320-0.","journal-title":"BMC Cancer"},{"key":"3493_CR79","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bioactmat.2023.03.018","volume":"27","author":"Y Chang","year":"2023","unstructured":"Chang Y, Jin G, Luo W, Luo Q, Jung J, Hummel SN, et al. Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy. Bioact Mater. 2023;27:168\u201380. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.03.018.","journal-title":"Bioact Mater"},{"issue":"357","key":"3493_CR80","doi-asserted-by":"publisher","first-page":"ra357123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):ra357123-357123. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2341.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3493_CR81","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","volume":"10","author":"Z Hu","year":"2020","unstructured":"Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):2815. https:\/\/doi.org\/10.1038\/s41598-020-59736-3.","journal-title":"Sci Rep"},{"key":"3493_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003050","author":"C-I Jan","year":"2021","unstructured":"Jan C-I, Huang S-W, Canoll P, Bruce JN, Lin Y-C, Pan C-M, et al. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-003050.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3493_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijrobp.2019.09.041","volume":"108","author":"KW Kim","year":"2020","unstructured":"Kim KW, Jeong J-U, Lee K-H, Uong TNT, Rhee JH, Ahn S-J, et al. Combined NK cell therapy and radiation therapy exhibit long-term therapeutic and antimetastatic effects in a human triple negative breast cancer model. Int J Radiat Oncol Biol Phys. 2020;108(1):115\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3493_CR84","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","volume":"363","author":"B Tao","year":"2023","unstructured":"Tao B, Du R, Zhang X, Jia B, Gao Y, Zhao Y, et al. Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy. J Control Release. 2023;363:692\u2013706. https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.007.","journal-title":"J Control Release"},{"key":"3493_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000450","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000450.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3493_CR86","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","volume":"40","author":"F Souza-Fonseca-Guimaraes","year":"2019","unstructured":"Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 2019;40(2):142\u201358. https:\/\/doi.org\/10.1016\/j.it.2018.12.003.","journal-title":"Trends Immunol"},{"key":"3493_CR87","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146\u201353. https:\/\/doi.org\/10.1016\/j.coi.2018.03.013.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3493_CR88","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351. PubMed PMID: 20179677; PubMed Central PMCID: PMCPMC2862534.","journal-title":"Mol Ther"},{"issue":"6","key":"3493_CR89","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1910607. (PubMed PMID: 32023374; PubMed Central PMCID: PMCPMC7101242).","journal-title":"N Engl J Med"},{"issue":"10","key":"3493_CR90","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"3493_CR91","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.esmoop.2021.100102","volume":"6","author":"F Schettini","year":"2021","unstructured":"Schettini F, Barbao P, Bras\u00f3-Maristany F, Galv\u00e1n P, Mart\u00ednez D, Par\u00e9 L, et al. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open. 2021;6(3):100102. PubMed PMID: 33838601; PubMed Central PMCID: PMCPMC8038941.","journal-title":"ESMO Open"},{"issue":"1","key":"3493_CR92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10(1):40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9. Epub 20240120.","journal-title":"Cell Death Discov"},{"issue":"2","key":"3493_CR93","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.trecan.2021.10.007","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Song X, Shen L, Wang X, Xu C. Exploiting T cell signaling to optimize engineered T cell therapies. Trends Cancer. 2022;8(2):123\u201334. https:\/\/doi.org\/10.1016\/j.trecan.2021.10.007.","journal-title":"Trends Cancer"},{"issue":"6667","key":"3493_CR94","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.add7034","volume":"382","author":"RL Vincent","year":"2023","unstructured":"Vincent RL, Gurbatri CR, Li F, Vardoshvili A, Coker C, Im J, et al. Probiotic-guided CAR-T cells for solid tumor targeting. Science. 2023;382(6667):211\u20138. https:\/\/doi.org\/10.1126\/science.add7034. Epub 20231012.","journal-title":"Science"},{"key":"3493_CR95","doi-asserted-by":"crossref","unstructured":"Wachsmann TL, Wouters AK, Remst DF, Hagedoorn RS, Meeuwsen MH, van Diest E, et al. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. Oncoimmunology. 2022;11(1):2033528.","DOI":"10.1080\/2162402X.2022.2033528"},{"issue":"6589","key":"3493_CR96","doi-asserted-by":"publisher","first-page":"eabl5282","DOI":"10.1126\/science.abl5282","volume":"376","author":"X Zhao","year":"2022","unstructured":"Zhao X, Kolawole EM, Chan W, Feng Y, Yang X, Gee MH, et al. Tuning T cell receptor sensitivity through catch bond engineering. Science. 2022;376(6589):eabl5282. https:\/\/doi.org\/10.1126\/science.abl5282.","journal-title":"Science"},{"issue":"12","key":"3493_CR97","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1111\/cas.15986","volume":"114","author":"A Wada","year":"2023","unstructured":"Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y, et al. Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain\u2010containing 5. Cancer Sci. 2023;114(12):4511\u201320. https:\/\/doi.org\/10.1111\/cas.15986.","journal-title":"Cancer Sci"},{"issue":"13","key":"3493_CR98","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"3","key":"3493_CR99","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jcyt.2018.11.004","volume":"21","author":"EL Hopewell","year":"2019","unstructured":"Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL. Tumor-infiltrating lymphocytes: streamlining a complex manufacturing process. Cytotherapy. 2019;21(3):307\u201314. https:\/\/doi.org\/10.1016\/j.jcyt.2018.11.004.","journal-title":"Cytotherapy"},{"issue":"16","key":"3493_CR100","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, et al. Breast cancers are immunogenic: Immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. 2022;40(16):1741\u201354. https:\/\/doi.org\/10.1200\/JCO.21.02170.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3493_CR101","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3390\/biomedicines11113037","volume":"11","author":"IF Faur","year":"2023","unstructured":"Faur IF, Dobrescu A, Clim AI, Pasca P, Prodan-Barbulescu C, Gherle BD, et al. The value of tumor infiltrating lymphocytes (TIL) for predicting the response to neoadjuvant chemotherapy (NAC) in breast cancer according to the molecular subtypes. Biomedicines. 2023;11(11):3037. https:\/\/doi.org\/10.3390\/biomedicines11113037.","journal-title":"Biomedicines"},{"issue":"2","key":"3493_CR102","doi-asserted-by":"publisher","first-page":"104120","DOI":"10.1016\/j.esmoop.2024.104120","volume":"10","author":"I Schlam","year":"2025","unstructured":"Schlam I, Loi S, Salgado R, Swain SM. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. ESMO Open. 2025;10(2):104120. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104120. Epub 20250117.","journal-title":"ESMO Open"},{"issue":"7","key":"3493_CR103","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/jco.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013;31(7):860\u20137. https:\/\/doi.org\/10.1200\/jco.2011.41.0902.","journal-title":"J Clin Oncol"},{"key":"3493_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000848","author":"JH van den Berg","year":"2020","unstructured":"van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000848.","journal-title":"J Immunother Cancer"},{"key":"3493_CR105","doi-asserted-by":"publisher","first-page":"1301025","DOI":"10.3389\/fimmu.2023.1301025","volume":"14","author":"L D\u00edaz-Alvarez","year":"2023","unstructured":"D\u00edaz-Alvarez L, L\u00f3pez-Cort\u00e9s GI, P\u00e9rez-Figueroa E. Immunomodulation exerted by galectins: a land of opportunity in rare cancers. Front Immunol. 2023;14:1301025. https:\/\/doi.org\/10.3389\/fimmu.2023.1301025.","journal-title":"Front Immunol"},{"issue":"9","key":"3493_CR106","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41551-023-01086-2","volume":"7","author":"AC Tremain","year":"2023","unstructured":"Tremain AC, Wallace RP, Lorentz KM, Thornley TB, Antane JT, Raczy MR, et al. Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. Nat Biomedical Eng. 2023;7(9):1142\u201355. https:\/\/doi.org\/10.1038\/s41551-023-01086-2.","journal-title":"Nat Biomedical Eng"},{"key":"3493_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147517","author":"K Dvir","year":"2024","unstructured":"Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25147517.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3493_CR108","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/14737140.2021.1951241","volume":"21","author":"ZC Hartman","year":"2021","unstructured":"Hartman ZC. How can we create precision immunotherapy as standard in breast cancer? Expert Rev Anticancer Ther. 2021;21(11):1179\u201381. https:\/\/doi.org\/10.1080\/14737140.2021.1951241.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"3493_CR109","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/1758834016658423","volume":"8","author":"C Migali","year":"2016","unstructured":"Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, et al. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol. 2016;8(5):360\u201374. https:\/\/doi.org\/10.1177\/1758834016658423.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"3493_CR110","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/life12121990","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang J, Hu T, Wang H, Long M, Liang B. Adverse events of PD-1 or PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Life (Basel). 2022;12(12):1990. https:\/\/doi.org\/10.3390\/life12121990.","journal-title":"Life (Basel)"},{"key":"3493_CR111","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","volume":"167","author":"LY Dirix","year":"2018","unstructured":"Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671\u201386. https:\/\/doi.org\/10.1007\/s10549-017-4537-5.","journal-title":"Breast Cancer Res Treat"},{"key":"3493_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106113","volume":"78","author":"H Du","year":"2020","unstructured":"Du H, Yi Z, Wang L, Li Z, Niu B, Ren G. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. Int Immunopharmacol. 2020;78:106113. https:\/\/doi.org\/10.1016\/j.intimp.2019.106113.","journal-title":"Int Immunopharmacol"},{"key":"3493_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146934","volume":"13","author":"J-Y Kim","year":"2023","unstructured":"Kim J-Y, Kim J, Cho EY, Park YH, Ahn JS, Kim K-M, et al. Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer. Front Oncol. 2023;13:1146934.","journal-title":"Front Oncol"},{"issue":"16","key":"3493_CR114","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"1","key":"3493_CR115","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"S-Y Wu","year":"2022","unstructured":"Wu S-Y, Xu Y, Chen L, Fan L, Ma X-Y, Zhao S, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer. 2022;21(1):84. https:\/\/doi.org\/10.1186\/s12943-022-01536-6.","journal-title":"Mol Cancer"},{"issue":"2","key":"3493_CR116","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/biomedicines12020369","volume":"12","author":"SS Said","year":"2024","unstructured":"Said SS, Ibrahim WN. Breaking barriers: the promise and challenges of immune checkpoint inhibitors in Triple-Negative breast cancer. Biomedicines. 2024;12(2):369. https:\/\/doi.org\/10.3390\/biomedicines12020369.","journal-title":"Biomedicines"},{"issue":"22","key":"3493_CR117","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1595.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3493_CR118","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/cgt.2008.55","volume":"16","author":"Y Gao","year":"2009","unstructured":"Gao Y, Whitaker-Dowling P, Griffin J, Barmada M, Bergman I. Recombinant vesicular stomatitis virus targeted to Her2\/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther. 2009;16(1):44\u201352. https:\/\/doi.org\/10.1038\/cgt.2008.55.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3493_CR119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","volume":"26","author":"L Liu","year":"2018","unstructured":"Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018;26(1):45\u201355. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.020.","journal-title":"Mol Ther"},{"issue":"11","key":"3493_CR120","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","volume":"23","author":"RH Vonderheide","year":"2017","unstructured":"Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer Res. 2017;23(11):2640\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2569.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"3493_CR121","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1158\/1078-0432.CCR-16-0190","volume":"22","author":"HL McArthur","year":"2016","unstructured":"McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, et al. A pilot study of preoperative single-dose ipilimumab and\/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res. 2016;22(23):5729\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0190.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3493_CR122","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","volume":"5","author":"ET Roussos Torres","year":"2024","unstructured":"Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, et al. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat Cancer. 2024;5(6):866\u201379. https:\/\/doi.org\/10.1038\/s43018-024-00729-w. Epub 20240214.","journal-title":"Nat Cancer"},{"issue":"1","key":"3493_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1524","volume":"11","author":"MR Sheen","year":"2019","unstructured":"Sheen MR, Fiering S. In situ vaccination: harvesting low hanging fruit on the cancer immunotherapy tree. WIREs Nanomed Nanobiotechnol. 2019;11(1):e1524.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"1","key":"3493_CR124","doi-asserted-by":"publisher","first-page":"21992","DOI":"10.1038\/s41598-021-01455-4","volume":"11","author":"T Yokoi","year":"2021","unstructured":"Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021;11(1):21992. https:\/\/doi.org\/10.1038\/s41598-021-01455-4. (Epub 20211109).","journal-title":"Sci Rep"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03493-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:25:50Z","timestamp":1760444750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03493-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3493"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03493-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is a review article. Hence, a research protocol requiring approval by the relevant institutional review board or ethics committee was not included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1858"}}